Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
ER

NASDAQ · ERAS

Erasca, Inc.

Healthcare · Biotechnology

$14.30

Down-$0.42 (-2.85%)

Updated Oct 7, 2026, 3:16 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
958.95M
P/E ratio
-7.47
Dividend yield
0.00%
52-week range
$2.11 – $24.28
Volume
8.04M
Avg. volume
1.84M

Price performance · ERAS

ERAS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

ERAS closed at $14.30 after 21 trading sessions, down 12.16% for the selected period.

Last close
$14.30
Period change
-12.16%
Period low
$13.95
Period high
$16.28
Daily close
View OHLC price history
ERAS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$14.74$14.93$14.02$14.308.04M
Oct 5, 2026$14.74$15.03$13.8034$14.725.49M
Oct 2, 2026$14.81$15.265$14.57$14.743.84M
Oct 1, 2026$14.66$15.01$14.33$14.583.69M
Sep 30, 2026$14.37$15.12$14.1101$14.665.29M
Sep 29, 2026$14.10$14.43$13.82$14.213.2M
Sep 28, 2026$14.525$14.615$13.86$14.133.6M
Sep 25, 2026$14.62$14.89$14.23$14.253.22M
Sep 24, 2026$13.82$15.07$13.535$14.526.27M
Sep 23, 2026$15.55$15.55$13.94$13.9454.42M
Sep 22, 2026$15.17$15.775$15.085$15.554.77M
Sep 21, 2026$14.96$15.29$14.60$15.044.15M
Sep 18, 2026$15.41$15.47$14.51$14.778.69M
Sep 17, 2026$15.83$16.32$14.92$15.347.55M
Sep 16, 2026$16.31$16.64$15.19$15.366.09M
Sep 15, 2026$16.135$16.29$15.535$16.254.69M
Sep 14, 2026$16.06$16.53$15.97$16.162.37M
Sep 11, 2026$16.05$16.54$15.87$15.882.88M
Sep 10, 2026$15.37$17.25$15.37$16.038.25M
Sep 9, 2026$16.06$16.70$15.67$15.704.04M
Sep 8, 2026$15.88$16.65$15.68$16.284.26M

Latest ERAS news

The latest Smart Investors Daily articles mentioning ERAS.

Stock researchCompany · Overview

ERAS research

Overview

Company profile and research snapshot.

Company profile

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.50
Implied upside
—
Analysts
16
ERAS recent ratings
DateFirmRatingTarget
Aug 14, 2026B of A SecuritiesNeutral—
Aug 13, 2026GuggenheimBuy—
Aug 12, 2026HC Wainwright & Co.Buy—
Jul 20, 2026Morgan StanleyEqual-Weight—
Jul 14, 2026B of A SecuritiesNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS TherapiesMELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a co

Yahoo · Sep 10, 2026

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trial Poster presentation to share nonclinical combination data of ERAS-0015 and ERAS-4001 demonstrating synergy in KRAS G12X-driven models SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on

Yahoo · Sep 8, 2026

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference being held at the New York Marriott Marquis in New York, NY. Management will participate in a fireside chat on Tuesday, September 15, 2026, at 1:05 pm Easte

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By